About Us new

Chief Strategy Officer

A strategic leader with over 25 years of experience in clinical development, Michał has supported more than 300 trials for pharma, biotech, and CROs worldwide—spanning oncology, rare diseases, and advanced modalities, including radiopharmaceutical programs and SaMD. As Chief Strategy Officer, he leads Axcellant’s commercial and partnership strategy, bringing CRO-and-CDMO perspective to feasibility, site readiness, imaging/dosimetry operations, and regulatory alignment. His mandate is clear: keep Axcellant’s boutique CRO model sharp, flexible, and built for small and mid-sized sponsors—delivering senior involvement, operational reliability, and speed.

Founder & CEO

Almost 20 years of experience in clinical research has led me to the Axcellant foundation – a unique Contract Research Organization (CRO) that delivers faster clinical research to a higher standard. Thanks to this approach, our team contributes robust clinical evidence generation to products that can improve patients' quality and extent of life.

Axcellant follows in the footsteps of ClinMed Pharma, a CRO that has offered services to pharmaceutical and biotech companies since 2006.

---

Axcellant’s team has experience in the nuances of the clinical development of small molecules, biological agents, and advanced therapeutics. We have supported and continue supporting pharmaceutical companies, medical devices manufacturers, non-commercial organisations, and institutions.

By conducting many complex and highly demanding projects, we have confirmed our competence, which we are now deepening in areas such as cardiology and nuclear medicine among others.

See any topics worth exploring together? Let’s meet for a quick call!.

Head of Operations & Regulatory

An experienced manager of complex, multi-country studies, Yana has delivered 30+ Phase I–IV trials across APAC, the US, and Europe—covering IMPs, medical devices, and ATMPs. A specialist in global regulatory oversight (FDA, EMA, PMDA), she drives end-to-end operations—from protocol design and CTIS submissions to risk mitigation—ensuring top-tier compliance (ICH GCP, ISO 14155) and moving every project toward successful approval.

Head of Quality Assurance

Quality Assurance Specialist with over 20 years of experience in the pharmaceutical and clinical trials industry, specializing in Good Clinical Practice (GCP). Extensive expertise in Clinical Site Audits, Vendor Qualification Audits, Internal System Audits, Mock Inspections, and SOP development. Skilled in Risk Assessment, Process Mapping, and CAPA Management, with a proven track record of conducting 300+ audits worldwide across Investigational Sites, Biotech, and CRO organizations. As a Quality Manager and Auditor, successfully established Quality Management Systems (QMS) in small and mid-sized companies. Possesses in-depth knowledge of ICH guidelines, GCP principles, and key FDA guidance for industry.

Head of PR & Digital Marketing

PR lead and Managing Partner at Presso, Axcellant’s communications partner for strategy, media relations, and analytics-driven outreach. Previously spent 6+ years in journalism, including as editor and reporter at Poland’s largest news TV channel. At Axcellant, he directs communications and media relations, shapes thought leadership and press materials, and prepares spokespeople—ensuring consistent visibility and disciplined execution across international markets.

A Professor of Cardiovascular Imaging at the University of Turku, Finland, and Director of the Turku PET Centre, a national research institute jointly operated by the University of Turku and Turku University Hospital. His research focuses on the physiology, pathophysiology, diagnosis, and treatment of coronary heart disease (CHD) and heart failure. He develops and applies novel non-invasive imaging methods – including PET, SPECT, echocardiography, MRI, and CT – to assess disease severity and risk and to guide therapy decisions. Professor Knuuti is the author or co-author of more than 800 scientific publications.

A Professor of Medicine and Cardiology in the Division of Artificial Intelligence in Medicine at Cedars-Sinai Medical Center in Los Angeles, and Professor of Medicine at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). He also serves as Director of Innovation in Imaging at Cedars-Sinai. His work has led to widely adopted software and algorithms for automated analysis of 3D cardiac images, contributing to innovations that support clinical decision-making and multicenter clinical studies worldwide. He has spearheaded large, international, multicenter imaging registries for SPECT and PET/CT – REFINE SPECT and REFINE PET – that aggregate imaging and clinical data from hospitals around the globe to advance AI-driven diagnosis and risk prediction in cardiology.

Knowledge

We combine knowledge and experience of medical, biostatistics, regulatory and clinical operations experts, to effectively conduct your research processes.

Technology

We implement the latest technologies, to improve, speed up and automate processes, thanks to which we are sure that the data we provide are reliable and credible, and the patients are safe.

Patient

We are all human. We can all become patients. We are aware of this, that's why everything we do, we do it with the greatest care, reliability and precision.